Analysts Question Commercial Viability of Marinus’ IV Ganaxolone After Interim Analysis Miss
Monday, in an interim analysis of Marinus Pharmaceuticals Inc’s (NASDAQ:MRNS) phase 3 RAISE trial, evaluating intravenous (IV) ganaxolone as a treatment for refractory status epilepticus (RSE), failed to meet pre-defined “stopping criteria.”
Marinus has completed RAISE enrollment at approximately 100 patients, with topline results expected in the summer of 2024.
The company said the future development of IV ganaxolone in refractory status epilepticus will be assessed following a review of the final RAISE study results.
An independent Data Monitoring Committee (DMC) recommended continuing the study.
Cantor Fitzgerald said it shifted focus to oral ganaxolone (O-GNX), which is progressing in the global Phase 3 TrustTSC study for tuberous …
Full story available on Benzinga.com